QLS31905 plus CAPOX vs Sintilimab plus CAPOX for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (QLS31905) combined with chemotherapy (CAPOX) against another immunotherapy (Sintilimab) plus chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if the new combination works better or is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is advanced or has spread and cannot be removed by surgery.
- You have not had any previous treatment for this advanced cancer.
- You are able to perform daily activities (ECOG 0-1).
- You have at least one measurable tumor as seen on scans.
- Your heart, liver, and kidneys are functioning well enough.
- You have not had another cancer in the last 5 years, and no serious heart or bleeding problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (QLS31905 and QL2107) plus standard chemotherapy for stomach cancer that has spread and tests positive for a specific marker (CLDN18.2). It's for people who haven't had treatment yet, and the goal is to see if it shrinks tumors better than standard care.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial tests a combination of three drugs — an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy — for a specific type of stomach cancer that produces high AFP and has spread to the liver. The goal is to see if this treatment can shrink tumors enough to make them removable by surgery.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.